(Q37874626)

24 August 2017

1 reference

title

Emerging drugs for schizophrenia. (English)

1 reference

24 August 2017

0 references

Falko Biedermann

1

1 reference

PubMed ID

21563991

24 August 2017

W Wolfgang Fleischhacker

series ordinal

2

1 reference

PubMed ID

21563991

24 August 2017

language of work or name

English

0 references

publication date

13 May 2011

1 reference

Expert Opinion on Emerging Drugs

24 August 2017

1 reference

24 August 2017

16

1 reference

24 August 2017

2

1 reference

24 August 2017

271-282

1 reference

Dopamine D1 receptors, regulation of gene expression in the brain, and neurodegeneration

24 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Molecular, pharmacological and functional diversity of 5-HT receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Localization of 5-HT(2A) receptors on dopamine cells in subnuclei of the midbrain A10 cell group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Brain dopamine and reward

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Signalling pathways associated with 5-HT6 receptors: relevance for cognitive effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

5-HT(7) receptors in the modulation of cognitive processes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Dopamine D1 receptor-mediated NMDA receptor insertion depends on Fyn but not Src kinase pathway in prefrontal cortical neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Glutamate as a therapeutic target in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

General Articles Muscarinic and Nicotinic Cholinergic Agonists: Structural Analogies and Discrepancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Cannabis and psychosis/schizophrenia: human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Activation of dopamine D1 receptors blocks phencyclidine-induced neurotoxicity by enhancing N-methyl-D-aspartate receptor-mediated synaptic strength

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Clozapine: dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Paliperidone extended release: a review of its use in the management of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Second-generation antipsychotic long-acting injections: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Effect of perospirone on P300 electrophysiological activity and social cognition in schizophrenia: a three-dimensional analysis with sloreta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Blonanserin: a review of its use in the management of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

BL-1020, a novel antipsychotic candidate with GABA-enhancing effects: D2 receptor occupancy study in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Glutamate-N-methyl-D-aspartate receptor modulation and minocycline for the treatment of patients with schizophrenia: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Initial phase 2 trial of a nicotinic agonist in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Galantamine improves cognition in schizophrenic patients stabilized on risperidone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

The effects of galantamine on psychopathology in chronic stable schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

Review and meta-analysis of usage of ginkgo as an adjunct therapy in chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2011.556112

10.1517/14728214.2011.556112

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21563991